1. Smith, Molly A, Choudhary, Gaurav S, Pellagatti, Andrea, Verma, Amit, Starczynowski, Daniel T. 2019. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. In Nature cell biology, 21, 640-650. doi:10.1038/s41556-019-0314-5. https://pubmed.ncbi.nlm.nih.gov/31011167/
2. Ngo, Vu N, Young, Ryan M, Schmitz, Roland, Chan, Wing C, Staudt, Louis M. 2010. Oncogenically active MYD88 mutations in human lymphoma. In Nature, 470, 115-9. doi:10.1038/nature09671. https://pubmed.ncbi.nlm.nih.gov/21179087/
3. Wang, Han, Zhou, Hao, Zhang, Quanri, Nagy, Laura E, Li, Xiaoxia. 2020. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice. In Journal of hepatology, 73, 1470-1481. doi:10.1016/j.jhep.2020.07.016. https://pubmed.ncbi.nlm.nih.gov/32682051/
4. Huang, Yuqing, Ning, Yi, Chen, Zhiwei, Duan, Wenhu, Xie, Hua. 2024. A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease. In Molecules (Basel, Switzerland), 29, . doi:10.3390/molecules29081803. https://pubmed.ncbi.nlm.nih.gov/38675622/
5. Winkler, Aaron, Sun, Weiyong, De, Saurav, Fleming, Margaret, Rao, Vikram R. 2021. The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial. In Arthritis & rheumatology (Hoboken, N.J.), 73, 2206-2218. doi:10.1002/art.41953. https://pubmed.ncbi.nlm.nih.gov/34423919/
6. Li, Qiong, Chen, Yali, Zhang, Daoxiang, Fields, Ryan C, Lim, Kian-Huat. 2019. IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer. In JCI insight, 4, . doi:10.1172/jci.insight.130867. https://pubmed.ncbi.nlm.nih.gov/31527315/
智鼠故事 
